Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

67.17USD
23 May 2019
Change (% chg)

$0.67 (+1.01%)
Prev Close
$66.50
Open
$66.75
Day's High
$67.46
Day's Low
$66.37
Volume
6,707,321
Avg. Vol
7,159,183
52-wk High
$79.61
52-wk Low
$60.32

Latest Key Developments (Source: Significant Developments)

Gilead Announces Data Demonstrating Non-Inferiority Of Descovy Vs. Truvada For HIV Infection Prevention
Wednesday, 6 Mar 2019 02:10pm EST 

March 6 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES DATA DEMONSTRATING NON-INFERIORITY OF ONCE-DAILY DESCOVY® VERSUS. ONCE-DAILY TRUVADA® FOR PREVENTION OF HIV INFECTION.DISCOVER TRIAL MEETS PRIMARY & SECONDARY ENDPOINTS & WILL SUPPORT SUPPLEMENTAL REGULATORY FILING FOR DESCOVY FOR PRE-EXPOSURE PROPHYLAXIS.DESCOVY AND TRUVADA WERE WELL TOLERATED AND HAD LOW DISCONTINUATION RATES DUE TO ADVERSE EVENTS OF 1.3 PERCENT AND 1.8 PERCENT, RESPECTIVELY.STATISTICALLY SIGNIFICANT ADVANTAGES WITH RESPECT TO CERTAIN LABORATORY PARAMETERS OBSERVED FOR THOSE GETTING DESCOVY VERSUS THOSE GETTING TRUVADA.  Full Article

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study Of Selonsertib In Compensated Cirrhosis Due To NASH
Monday, 11 Feb 2019 04:30pm EST 

Feb 11 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES TOPLINE DATA FROM PHASE 3 STELLAR-4 STUDY OF SELONSERTIB IN COMPENSATED CIRRHOSIS (F4) DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH).GILEAD SCIENCES - STELLAR-4 DID NOT MEET PRE-SPECIFIED WEEK 48 PRIMARY ENDPOINT OF A ≥ 1-STAGE HISTOLOGIC IMPROVEMENT IN FIBROSIS WITHOUT WORSENING OF NASH..GILEAD SCIENCES INC - SELONSERTIB WAS GENERALLY WELL-TOLERATED AND SAFETY RESULTS WERE CONSISTENT WITH PRIOR STUDIES.GILEAD SCIENCES INC - WILL WORK WITH DATA MONITORING COMMITTEE AND INVESTIGATORS TO CONCLUDE STELLAR-4 STUDY.  Full Article

Gilead Sciences Announces 11 Percent Increase In First Quarter 2019 Dividend
Monday, 4 Feb 2019 04:02pm EST 

Feb 4 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES 11 PERCENT INCREASE IN FIRST QUARTER 2019 DIVIDEND.GILEAD SCIENCES INC - SETS QUARTERLY DIVIDEND OF $0.63 PER SHARE OF COMMON STOCK.  Full Article

Gilead Sciences Announces Q4 Adj EPS Of $1.44
Monday, 4 Feb 2019 04:01pm EST 

Feb 4 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.NET INCOME FOR Q4 $0.00 EARNINGS PER DILUTED SHARE.TOTAL REVENUES FOR Q4 OF 2018 WERE $5.8 BILLION COMPARED TO $5.9 BILLION FOR SAME PERIOD IN 2017.EARNINGS PER SHARE FOR Q4 OF 2018 INCLUDED AN UNFAVORABLE IMPACT OF $0.99 PER DILUTED SHARE.NON-GAAP NET INCOME FOR Q4 OF 2018 WAS $1.44 PER DILUTED SHARE.SEES FY 2019 PRODUCT SALES $21,300 MILLION - $21,800 MILLION.GILEAD SCIENCES - SEES 2019 DILUTED EPS IMPACT OF ACQUISITION-RELATED, UP-FRONT COLLABORATION, STOCK-BASED COMPENSATION, OTHER EXPENSES OF $1.40 - $1.50 PER SHARE.FY2019 EARNINGS PER SHARE VIEW $6.73, REVENUE VIEW $21.76 BILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE VIEW $1.70, REVENUE VIEW $5.50 BILLION -- REFINITIV IBES DATA.QTRLY HARVONI SALES $232 MILLION VERSUS $644 MILLION REPORTED LAST YEAR.  Full Article

Gilead Sciences Names Daniel O’Day Chairman And Chief Executive Officer
Monday, 10 Dec 2018 01:00am EST 

Dec 10 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES NAMES DANIEL O’DAY CHAIRMAN AND CHIEF EXECUTIVE OFFICER.APPOINTED GREGG ALTON AS INTERIM CHIEF EXECUTIVE OFFICER FOR PERIOD OF JANUARY 1, 2019 UNTIL O'DAY'S START DATE OF MARCH 1, 2019.APPOINTMENT OF DANIEL O'DAY AS CHAIRMAN OF BOARD AND CHIEF EXECUTIVE OFFICER IS EFFECTIVE MARCH 1, 2019.  Full Article

Target PharmaSolutions Collaborates With Gilead On NASH, Hep B Research
Tuesday, 20 Nov 2018 08:30am EST 

Nov 20 (Reuters) - TARGET PharmaSolutions Inc::TARGET PHARMASOLUTIONS TO ADVANCE RESEARCH IN NASH AND HEPATITIS B THROUGH NEW COLLABORATION WITH GILEAD SCIENCES.TARGET PHARMASOLUTIONS SAYS GILEAD IS 6TH PARTNER IN TARGET-NASH, JOINING ALLERGAN, BOEHRINGER INGELHEIM, BRISTOL-MYERS SQUIBB, INTERCEPT AND NOVARTIS.  Full Article

Gilead Sciences Says China NMPA Approves Vemlidy For Chronic Hepatitis B Virus Infection
Sunday, 18 Nov 2018 10:00pm EST 

Nov 18 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES SAYS CHINA NMPA APPROVES GILEAD'S VEMLIDY (TENOFOVIR ALAFENAMIDE) FOR CHRONIC HEPATITIS B VIRUS (HBV) INFECTION.  Full Article

Gilead Announces Positive Phase 2 Results For Gs-9674 In Primary Sclerosing Cholangitis
Friday, 9 Nov 2018 08:00am EST 

Nov 9 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES POSITIVE PHASE 2 RESULTS FOR GS-9674 IN PRIMARY SCLEROSING CHOLANGITIS (PSC) AT THE LIVER MEETING® 2018.GILEAD SCIENCES INC - GS-9674 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FOOD AND DRUG ADMINISTRATION.GILEAD SCIENCES INC - GS-9674 WAS WELL TOLERATED.GILEAD SCIENCES INC - GS-9674 WAS WELL TOLERATED.GILEAD SCIENCES INC - TREATMENT WAS DISCONTINUED DUE TO ADVERSE EVENTS IN THREE PATIENTS TREATED WITH GS-9674 100 MG.GILEAD SCIENCES INC - ONE DISCONTINUATION DUE TO PRURITUS, AND ONE PATIENT WITH PLACEBO IN TRIAL.  Full Article

Gilead Sciences, Tango Therapeutics Announce Strategic Collaboration
Wednesday, 31 Oct 2018 08:30am EDT 

Oct 31 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND TANGO THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NEXT-GENERATION TARGETED IMMUNO-ONCOLOGY THERAPIES.GILEAD SCIENCES SAYS TANGO WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION UNDER TERMS OF DEAL.GILEAD SCIENCES SAYS TANGO WILL ALSO BE ELIGIBLE TO RECEIVE ABOUT $1.7 BILLION IN ADDITIONAL PAYMENTS ACROSS PROGRAMS.GILEAD SCIENCES SAYS TANGO WILL ALSO BE ELIGIBLE TO RECEIVE UP TO LOW DOUBLE-DIGIT TIERED ROYALTIES ON NET SALES UNDER TERMS OF DEAL.GILEAD SCIENCES SAYS FOR PROGRAMS TANGO OPTS TO CO-DEVELOP & CO-DETAIL, PARTIES WILL SPLIT PROFITS & LOSSES 50/50 FOR U.S..GILEAD SCIENCES - FOR PROGRAMS TANGO OPTS TO CO-DEVELOP & CO-DETAIL, TANGO WILL BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS & ROYALTIES ON EX-U.S. SALES.GILEAD SCIENCES SAYS UNDER MULTI-YEAR COLLABORATION, TANGO WILL PERFORM TARGET DISCOVERY & VALIDATION.GILEAD SCIENCES SAYS WILL HAVE OPTIONS TO WORLDWIDE RIGHTS ON UP TO 5 TARGETS FROM TANGO’S PROPRIETARY FUNCTIONAL GENOMICS-BASED DISCOVERY PLATFORM.GILEAD SCIENCES SAYS COLLABORATION DOES NOT INCLUDE TANGO’S LEAD PROGRAMS, FOR WHICH TANGO WILL RETAIN ALL RIGHTS.  Full Article

Gilead Sciences Announces Fourth Quarter 2018 Dividend
Thursday, 25 Oct 2018 04:02pm EDT 

Oct 25 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES FOURTH QUARTER 2018 DIVIDEND.GILEAD SCIENCES INC - DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q4 OF 2018.  Full Article

Photo

Gilead to separate Kite cell therapy unit, posts higher profit

Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.